Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials

References

• Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998;46:135–46.
   PubMed Web of Science ®Google Scholar
• Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-a systematic review and meta-analysis. Radiother Oncol 2011;100:22–32.
   PubMed Web of Science ®Google Scholar
• Overgaard J. Hypoxic radiosensitization: Adored and ignored. J Clin Oncol 2007;25:4066–74.
   PubMed Web of Science ®Google Scholar
• Toustrup K, Sørensen BS, Nordsmark M, Busk M, Wiuf C, Alsner J, et al. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res 2011;71:5923–31.
   PubMed Web of Science ®Google Scholar
• Sørensen BS, Toustrup K, Horsman MR, Overgaard J, Alsner J. Identifying pH independent hypoxia induced genes in human squamous cell carcinomas in vitro. Acta Oncol 2010;49:895–905.
   PubMed Web of Science ®Google Scholar
• Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 2000;57:39–43.
   PubMed Web of Science ®Google Scholar
• Toustrup K, Sørensen BS, Lassen P, Wiuf C, Alsner J, Overgaard J. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol 2012;102:122–9.
   PubMed Web of Science ®Google Scholar
• Linge A, Lock S, Gudziol V, Nowak A, Lohaus F, von NC, et al. Low cancer stem cell marker expression and low hypoxia identify good prognosis subgroups in HPV(-) HNSCC after postoperative radiochemotherapy: A Multicenter Study of the DKTK-ROG. Clin Cancer Res 2016. [Epub ahead of print]. DOI: 10.1158/1078-0432.CCR-15-1990.
   PubMed Web of Science ®Google Scholar
• Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol 2010;94:30–5.
   PubMed Web of Science ®Google Scholar
• Lassen P. The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiother Oncol 2010;95:371–80.
   PubMed Web of Science ®Google Scholar
• Lassen P, Primdahl H, Johansen J, Kristensen CA, Andersen E, Andersen LJ, et al. Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer. Radiother Oncol 2014;113:310–16.
   PubMed Web of Science ®Google Scholar
• Bentzen J, Toustrup K, Eriksen JG, Primdahl H, Andersen LJ, Overgaard J. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study. Acta Oncol 2015;54:1001–7.
   PubMed Web of Science ®Google Scholar
• Baujat B, Bourhis J, Blanchard P, Overgaard J, Ang KK, Saunders M, et al. Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev 2010;12:CD002026.
   PubMed Web of Science ®Google Scholar
• Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site. Radiother Oncol 2011;100:33–40.
   PubMed Web of Science ®Google Scholar
• Tawk B, Schwager C, Deffaa O, Dyckhoff G, Warta R, Linge A, et al. Comparative analysis of transcriptomics based hypoxia signatures in in head- and neck squamous cell carcinoma. Radiother Oncol 2016;118:350–8.
   PubMed Web of Science ®Google Scholar
• Hassan Metwally MA, Ali R, Kuddu M, Shouman T, Strojan P, Iqbal K, et al. IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma. Radiother Oncol 2015;116:15–20.
   PubMed Web of Science ®Google Scholar
• Thomson D, Yang H, Baines H, Miles E, Bolton S, West C, et al. NIMRAD – a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer. Clin Oncol (R Coll Radiol) 2014;26:344–7.
   PubMed Web of Science ®Google Scholar
• Eustace A, Mani N, Span PN, Irlam JJ, Taylor J, Betts GN, et al. A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. Clin Cancer Res 2013;19:4879–88.
   PubMed Web of Science ®Google Scholar
• Betts GN, Eustace A, Patiar S, Valentine HR, Irlam J, Ramachandran A, et al. Prospective technical validation and assessment of intra-tumour heterogeneity of a low density array hypoxia gene profile in head and neck squamous cell carcinoma. Eur J Cancer 2013;49:156–65.
   PubMed Web of Science ®Google Scholar
• Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol 2012;105:14–20.
   PubMed Web of Science ®Google Scholar
• Toustrup K, Sørensen BS, Alsner J, Overgaard J. Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy. Semin Radiat Oncol 2012;22:119–27.
   PubMed Web of Science ®Google Scholar
• Harris BH, Barberis A, West CM, Buffa FM. Gene expression signatures as biomarkers of tumour hypoxia. Clin Oncol (R Coll Radiol) 2015;27:547–60.
   PubMed Web of Science ®Google Scholar
• Søes S, Sørensen BS, Alsner J, Overgaard J, Hager H, Hansen LL, et al. Identification of accurate reference genes for RT-qPCR analysis of formalin-fixed paraffin-embedded tissue from primary non-small cell lung cancers and brain and lymph node metastases. Lung Cancer 2013;81:180–6.
   PubMed Web of Science ®Google Scholar
• Sørensen BS, Busk M, Olthof N, Speel EJ, Horsman MR, Alsner J, et al. Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells. Radiother Oncol 2013;108:500–5.
   PubMed Web of Science ®Google Scholar
• Jensen AR, Nellemann HM, Overgaard J. Tumor progression in waiting time for radiotherapy in head and neck cancer. Radiother Oncol 2007;84:5–10.
   PubMed Web of Science ®Google Scholar
• van Harten MC, Hoebers FJ, Kross KW, van Werkhoven ED, van den Brekel MW, van Dijk BA. Determinants of treatment waiting times for head and neck cancer in the Netherlands and their relation to survival. Oral Oncol 2015;51:272–8.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 2012;9:674–87.
   PubMed Web of Science ®Google Scholar